Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
3.410
+0.170 (5.25%)
Feb 6, 2026, 4:00 PM EST - Market closed
Oramed Pharmaceuticals Revenue
Revenue (ttm)
$2.00M
Revenue Growth
n/a
P/S Ratio
70.49
Revenue / Employee
$500,000
Employees
4
Market Cap
135.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.34M | -1.36M | -50.43% |
| Dec 31, 2022 | 2.70M | - | - |
| Aug 31, 2021 | 2.70M | -7.00K | -0.26% |
| Aug 31, 2020 | 2.71M | 7.00K | 0.26% |
| Aug 31, 2019 | 2.70M | 254.00K | 10.37% |
| Aug 31, 2018 | 2.45M | -7.00K | -0.29% |
| Aug 31, 2017 | 2.46M | 1.82M | 283.15% |
| Aug 31, 2016 | 641.00K | - | - |
| Aug 31, 2015 | - | - | - |
| Aug 31, 2014 | - | - | - |
| Aug 31, 2013 | - | - | - |
| Aug 31, 2012 | - | - | - |
| Aug 31, 2011 | - | - | - |
| Aug 31, 2010 | - | - | - |
| Aug 31, 2009 | - | - | - |
| Aug 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 148.20M |
| Sutro Biopharma | 105.65M |
| Spero Therapeutics | 40.55M |
| Whitehawk Therapeutics | 14.38M |
| Fate Therapeutics | 7.14M |
| Cibus | 3.79M |
| Connect Biopharma Holdings | 762.00K |
ORMP News
- 26 days ago - Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company - GlobeNewsWire
- 26 days ago - Oramed and Lifeward Announce Strategic Transaction - PRNewsWire
- 4 weeks ago - Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments - PRNewsWire
- 6 weeks ago - Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback - Seeking Alpha
- 2 months ago - Oramed Reports Fiscal Third Quarter 2025 Financial Results - PRNewsWire
- 2 months ago - ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS - PRNewsWire
- 3 months ago - Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives - PRNewsWire
- 10 months ago - Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals - GlobeNewsWire